TOPLINE:

Among patients with type 2 diabetes (T2D) initiating oral glucose-lowering monotherapy, a history of clinically diagnosed depression — especially a recent episode — was associated with the earlier addition or switching of a medication class and insulin initiation than no prior depression.

METHODOLOGY:

• Researchers in England conducted a retrospective cohort study using real-world primary care data from 2011 to 2023 to assess whether a history of depression and its timing are associated with the progression of diabetes treatment in patients with T2D.
• They analysed 378,935 patients with T2D aged 35 years or older who initiated their first-ever single oral glucose-lowering monotherapy and had been registered at practice for at least 90 days before the diagnosis of T2D.
• A history of depression was categorised by the timing of the most recent clinical code recorded before monotherapy initiation: recent depression (≤ 1.7 years; n = 23,765), intermediate depression (1.7-12.8 years; n = 47,492), distant depression (> 12.8 years; n = 23,752), or no prior depression (n = 282,926).
• Outcomes were the time to treatment intensification (adding a second glucose‑lowering drug or switching to a different class) and the time to insulin initiation.
• The median follow-up duration after monotherapy initiation was 1.8 years for treatment intensification and 4.7 years for insulin initiation.

TAKEAWAY:

• Compared with no prior depression, recent depression was associated with higher odds of both treatment intensification (odds ratio [OR], 1.20; 95% CI, 1.17-1.23) and insulin initiation (OR, 1.29; 95% CI, 1.23-1.36).
• Intermediate depression was also linked to higher odds of treatment intensification (OR, 1.12; 95% CI, 1.10-1.15) and insulin initiation (OR, 1.22; 95% CI, 1.18-1.27), whereas distant depression showed smaller associations, indicating a gradient by recency.
• At 5 years after monotherapy initiation, recent depression was associated with a modestly higher absolute risk for treatment intensification (3.9%; 95% CI, 3.4%-4.5%) and insulin initiation (1.4%; 95% CI, 1.1%-1.7%); on average, intensification occurred 2 months earlier, and insulin initiation occurred about half a month earlier.

IN PRACTICE:

"[The study] findings highlight the importance of integrating mental health support into diabetes care," the authors wrote.

SOURCE:

This study was led by Alexandra C. Gillett, King's College London, London, England. It was published online on April 08, 2026, in Primary Care Diabetes.

LIMITATIONS:

Unmeasured factors such as depression severity, psychosocial stressors, and social support may still have confounded the results. Reverse causation could not be ruled out, especially for recent depression, for which worsening glycaemic control may have contributed to symptoms. Treatment progression did not include dose increases within the same drug class, which may have underestimated early treatment intensification.

DISCLOSURES:

This study was supported by the Medical Research Council and was partly funded by the National Institute for Health and Care Research Maudsley Biomedical Research Centre at South London and Maudsley NHS Trust and King's College London. The authors disclosed having no relevant conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.